Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T)

Vascular Health and Risk Management

Volumn 7, Issue 1, 2011, Pages 85-95

  Bönner, Gerd ^a   Landers, Bernhard ^b   Bramlage, Peter ^c  

^a Park Klinikum Bad Krozingen   (Germany)

^b Diabetes Center   (Germany)

^c Institute for Cardiovascular Pharmacology and Epidemiology   (Germany)

Author keywords

Candesartan cilexetil; Combination therapy; Diuretics; Essential hypertension; High dose monotherapy; Noninterventional study; Phase IV

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; BIPHENYL DERIVATIVE; CANDESARTAN HEXETIL; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; TETRAZOLE DERIVATIVE;

AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; FEMALE; GERMANY; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIURETICS; DRUG COMBINATIONS; FEMALE; GERMANY; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 79958264637     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S17004     Document Type: Article

References (46)

1. Lacourciere Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan Study Investigators. Am J Hypertens. 1999;12: 1181-1187.
2. Andersson OK, Neldam S. A comparison of the antihypertensive effects of candesartan cilexetil and losartan in patients with mild to moderate hypertension. J Hum Hypertens. 1997;11 Suppl 2:S63-S64.
3. Farsang C, Kawecka-Jaszcz K, Langan J, et al. Antihypertensive effects and tolerability of candesartan cilexetil alone and in combination with amlodipine. Clin Drug Invest. 2001;21:17-13.
4. Himmelmann A, Keinanen-Kiukaanniemi S, Wester A, et al. The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension. Blood Press. 2001;10:43-51.
5. Philipp T, Letzel H, Arens HJ. Dose-finding study of candesartan cilexetil plus hydrochlorothiazide in patients with mild to moderate hypertension. J Hum Hypertens. 1997;11 Suppl 2: S67-S68.
6. Koenig W. The Multicentre Study Group. Comparison of the efficacy and tolerability of combination tablets containing candesartan cilexetil and hydrochlorothiazide or losartan and hydrochlorothiazide in patients with moderate to severe hypertension. Results of the CARLOS study. Clin Drug Investig. 2000;19:239-246.
7. Bönner G, Fuchs W. Fixed combination of candesartan with hydrochlorothiazide in patients with severe primary hypertension. Curr Med Res Opin. 2004;20:597-602.
8. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772-776.
9. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759-766.
10. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362: 777-781.
11. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-convertingenzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362: 767-771.
12. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321:1440-1444.
13. Trenkwalder P, Lehtovirta M, Dahl K. Long-term treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in mild hypertensives with type II diabetes. J Hum Hypertens. 1997;11 Suppl 2:S81-S83.
14. Rossing K, Christensen PK, Hansen BV, et al. Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study. Diabetes Care. 2003;26:150-155.
15. Rossing K, Jacobsen P, Pietraszek L, et al. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care. 2003;26:2268-2274.
16. Bilous R, Chaturvedi N, Sjolie AK, et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med. 2009;151:11-20, W3-W4.
17. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875-886.
18. Schrader J, Lüders S, Kulschewski A, et al. The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke. 2003;34:1699-1703.
19. Shargorodsky M, Hass E, Boaz M, et al. High dose treatment with angiotensin II receptor blocker in patients with hypertension: differential effect of tissue protection versus blood pressure lowering. Atherosclerosis. 2008;197:303-310.
20. Baumgart P, Reismann J, Pohlmeyer H, et al. Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment). Dtsch Med Wochenschr. 2001;126:547-550.
21. Mancia G, de Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-1187.
22. Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
23. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press. 2009;18: 308-347.
24. Bramlage P, Schonrock E, Odoj P. Metabolic effects of an AT1-receptor blockade combined with HCTZ in cardiac risk patients: a non interventional study in primary care. BMC Cardiovasc Disord. 2008;8:30.
25. Oparil S, Michelson EL. Long term efficacy, safety, and tolerability of candesartan cilexetil added to hydrochlorothiazide in patients with severe hypertension. Am J Hypertens. 2009;1:20.
26. Edes I. Combination therapy with candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg provides the full additive antihypertensive effect of the components: a randomized, double-blind, parallel-group study in primary care. Clin Drug Investig. 2009;29:293-304.
27. Bramlage P, Schonrock E, Odoj P, et al. Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with Candesartan/HCTZ. MMW Fortschr Med. 2008; 149 Suppl 4:172-181.
28. Uen S, Un I, Fimmers R, et al. Effect of candesartan cilexetil with hydrochlorothiazide on blood pressure and ST-segment depression in patients with arterial hypertension. Dtsch Med Wochenschr. 2007; 132:81-86.
29. Bönner G; Multicentre Study Group. Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy. Blood Press Suppl 2008;2: 22-30.
30. Ohma KP, Milon H, Valnes K. Efficacy and tolerability of a combination tablet of candesartan cilexetil and hydrochlorothiazide in insufficiently controlled primary hypertension: comparison with a combination of losartan and hydrochlorothiazide. Blood Press. 2000;9:214-220.
31. Karlson BW, Zetterstrand S, Olofsson B, et al. A dose-response analysis of candesartan-hydrochlorothiazide combination therapy in patients with hypertension. Blood Press. 2009;18:149-156.
32. Waeber B. Very-low-dose combination: a first-line choice for the treatment of hypertension? J Hypertens Suppl. 2003;21:S3-S10.
33. Waeber B. Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertension. Expert Rev Cardiovasc Ther. 2003;1:43-50.
34. Burgess E, Muirhead N, Cotret PP, et al, and the SMART (Supra Maximal Atacand Renal Trial) Investigators. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol. 2009;20: 893-900.
35. Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326:1427.
36. Burnier M. Angiotensin II type 1 receptor blockers. Circulation. 2001; 103:904-912.
37. Salerno CM, Demopoulos L, Mukherjee R, et al. Combination angiotensin receptor blocker/hydrochlorothiazide as initial therapy in the treatment of patients with severe hypertension. J Clin Hypertens (Greenwich). 2004;6:614-620.
38. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
39. Ruggenenti P, Perna A, Mosconi L, et al. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney Int. 1998;53:1209-1216.
40. De Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004;110:921-927.
41. De Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65:2309-2320.
42. Schmieder RE, Schrader J, Zidek W, et al. Low-grade albuminuria and cardiovascular risk: what is the evidence? Clin Res Cardiol. 2007;96: 247-257.
43. Mancia G, de Backer G, Dominiczak A, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens. 2007;25:1751-1762.
44. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121-2158.
45. Nash DT. Rationale for combination therapy in hypertension management: focus on angiotensin receptor blockers and thiazide diuretics. South Med J. 2007;100:386-392.
46. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342:1887-1892.